Li Y 2012.

Study characteristics
Methods	RCT, single centre, 70 participants, 1 year duration
Participants	70 enrolled: CHM = 35, control = 35, 22 to 39 years, baseline was comparable 70 analysed/evaluated: CHM = 35, control = 35 Age (years): CHM 28.5 ± 3.8, control 26.2 ± 3.6 Subfertility time (years): CHM 5 ± 2.7, control 4.6 ± 2.4 PCOS DC: consistent with Rotterdam criteria (evaluated by review authors) In: PCOS, infertility, 20 to 40 years Ex: using hormone or drugs for ovulation induction in the last 3 months, tubal infertility, uterine infertility, male sterility
Interventions	CHM: Xuanju capsule (day 3 of menstrual cycle, 3 pills, tid, 4 weeks), clomiphene (day 3 of menstrual cycle, 50 mg, once a day, 5 days), HCG was injected when dominant follicle was present, if dominant follicle was absent until the 20th day of menstrual cycle, progesterone was injected 20 mg, once a day, 5 days Control: clomiphene (day 3 of menstrual cycle, 50 mg, once a day, 5 days), HCG was injected when dominant follicle was present, if dominant follicle was absent until the 20th day of menstrual cycle, progesterone was injected 20 mg, once a day, 5 days Duration: treatment until pregnancy but no more than 3 cycles; follow‐up duration was unclear
Outcomes	Pregnancy rate (per woman) Ovulation rate (per cycle)
Notes	Xuanju capsule: Zhejiang Shiqiang Pharmaceutical Company, batch number: Z20060462
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table
Allocation concealment (selection bias)	Unclear risk	We were unable to contact the study authors for more information.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	We were unable to contact the study authors for more information.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	We were unable to contact the study authors for more information.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No withdrawal or dropout was reported.
Selective reporting (reporting bias)	Unclear risk	The study protocol was unavailable.
Other bias	Low risk	No other potential risk of bias identified.